Related Experiment Video
Updated: Jul 9, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Emerging Precision Medicine Approaches for Lung Neuroendocrine Tumors
1Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94158, USA.
Abstract:
Well-differentiated lung neuroendocrine tumors (LNETs) are heterogeneous cancers that are increasing in incidence. Treatment options for LNETs have expanded in recent years, and our knowledge of the molecular subtypes has also advanced. Multidisciplinary teams have an established role in personalizing the best treatment for individual patients. Other precision medicine approaches for the treatment of LNETs have lagged behind those for non-small-cell lung cancer, with only rare actionable molecular alterations identified and few established predictive factors to guide therapy selection. However, as summarized in this review, there is increasing potential for personalized treatment of patients with LNETs. In particular, advances in radiotheragnostics may allow us to tailor the treatment of individual patients with NETs in the coming years. These advances may soon deliver the promise of more effective, less toxic treatments and better outcomes for patients with these increasingly common cancers.
Insights
Lung neuroendocrine tumors (LNETs) are complex cancers with expanding treatment options. Advances in radiotheragnostics show promise for personalized, more effective therapies for LNETs patients.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Well-differentiated lung neuroendocrine tumors (LNETs) represent a heterogeneous and increasing cancer incidence.
- Current treatment strategies for LNETs are evolving, alongside a growing understanding of their molecular subtypes.
- Personalized treatment approaches for LNETs have historically lagged behind other lung cancers, such as non-small-cell lung cancer.
Purpose of the Study:
- To review the current landscape and future potential of personalized medicine for lung neuroendocrine tumors.
- To highlight advances in radiotheragnostics as a key area for tailoring LNET treatment.
- To discuss the potential for improved patient outcomes through precision oncology.
Main Methods:
- Literature review focusing on recent advancements in LNET treatment and molecular characterization.
- Analysis of emerging precision medicine strategies, including radiotheragnostics.
- Synthesis of information on multidisciplinary team roles in LNET patient care.
Main Results:
- While few actionable molecular alterations are identified in LNETs, personalized treatment potential is increasing.
- Radiotheragnostics represent a significant advancement for tailoring treatments to individual LNET patients.
- Multidisciplinary teams are crucial for optimizing individualized LNET treatment plans.
Conclusions:
- Personalized treatment for LNETs is gaining momentum, driven by molecular insights and new therapeutic modalities.
- Radiotheragnostics are poised to revolutionize LNET treatment by enabling highly tailored therapeutic decisions.
- Future advancements promise more effective, less toxic treatments and improved outcomes for patients with LNETs.
